Research progress in the treatment of pulmonary sarcomatoid carcinoma
10.3969/j.issn.1671-8348.2025.04.038
- VernacularTitle:肺肉瘤样癌治疗的研究进展
- Author:
Xiaoling JIAO
1
;
Rongli SUN
;
Jingyi ZHANG
;
Fengjuan LIU
Author Information
1. 山东第二医科大学临床医学院,山东潍坊 261000
- Keywords:
pulmonary sarcomatoid carcinoma;
non-small cell lung cancer;
programmed death receptor-1;
programmed death receptor-ligand 1
- From:
Chongqing Medicine
2025;54(4):1005-1009
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary sarcomatoid carcinoma(PSC)is a group of rare non-small cell lung cancers that are highly aggressive,prone to metastasis and recurrence and have poor prognosis.They are usually diagnosed at an advanced stage,when surgery is no longer an option,and are unresponsive to radiotherapy and chemo-therapy.The research found that PSC's programmed death receptor-1/programmed death receptor-ligand 1 was highly expressed and most of them had genetic mutations.Chinese medicines are widely used in clinical treatment for various malignant tumors due to their multi-targeting characteristics,low side effects,and good efficacy,demonstrating significant anti-tumor effects.Given the breakthrough success of immunotherapy and targeted therapy in recent years,the article promises to provide new ideas and targets for treating this highly malignant disease with a poor prognosis.
